Return to Newsroom Share on Facebook Share on LinkedIn Share on X October 07, 2024 Given the popularity of GLP-1 medications, its not surprising that health food and supplement brands are trying to capitalize on the trend, says Michael Snyder, MD, an in-house obesity specialist at FuturHealth and medical director of the Bariatric Surgery Center at Rose Medical Center
A study investigating the acute anti-hypertensive effect of anti-oxidant agents in hypertensive subjects and diabetic patients found that the anti-oxidant GSH showed a significant hypotensive effect probably due to the control exerted over the nitric oxide-free radical interaction [96]
Barriers to initiating treatment may include delayed recognition of obesity as a disease by public health and medical organizations, provider biases regarding patients with obesity, lack of reimbursement leading to out-of-pocket costs to patients, inadequate training of providers, historical safety issues with AOMs, and perceptions of patients and their caregivers regarding the efficacy of AOMs [14,15,16,17]
PMID 27592340